The votes have been counted, and a decision has been rendered — no, not on the winner of the U.S. Presidential election (unfortunately), but on Biogen’s (BIIB) aducanumab Alzheimer’s drug.By a vote of one for, eight against, and two abstaining, the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee concluded Friday that positive clinical data from Biogen’s “EMERGE” trial, when “viewed independently and without regard for” data from the company’s “ENGAGE” trial, were not sufficient to convince it that aducanumab is an effective treatment for Alzheimer’s.The Advisory Committee furthermore voted zero to seven …read more
Source:: Yahoo Finance
